As part of the Tribendimidine (TrBD) Consortium, PATH and partners are advancing TrBD—an anthelmintic drug with demonstrated excellent efficacy against soil-transmitted helminth (STH) infections—as an additional drug option for control and treatment of STH. Integration of TrBD into global mass drug administration campaigns could accelerate progress to eliminate STH in endemic regions.
Corporate author(s): PATH
Publication date: August 2017
635 KB PDF
Hard copies are not available.
Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.
Related regions: Global
- Emerging and epidemic diseases > Drug development
- For advocates and policymakers > Public-private partnerships
For more information…
Contact: PATH Publications
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA